Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$279.83
+0.2%
$318.52
$261.59
$468.45
$7.98B0.94222,366 shs196,160 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
+0.19%+1.41%-14.74%-12.67%-39.67%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
4.6244 of 5 stars
3.43.00.04.21.93.31.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
2.80
Moderate Buy$468.0067.24% Upside

Current Analyst Ratings

Latest BIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$400.00 ➝ $365.00
2/16/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$395.00 ➝ $420.00
2/16/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$484.00 ➝ $480.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.67B2.99$12.13 per share23.07$306.51 per share0.91

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-$637.32M-$21.49N/A24.42N/A-23.86%3.90%2.77%5/7/2024 (Confirmed)

Latest BIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.04N/A-$2.04N/AN/AN/A  
2/15/2024Q4 2023
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.93$3.10+$0.17-$5.94$685.00 million$681.18 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.14
5.83
4.34

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
65.24%

Insider Ownership

CompanyInsider Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
17.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
8,03028.52 million23.65 millionOptionable

BIO Headlines

SourceHeadline
Infrared And Terahertz Spectroscopy Market Growing Demand to Boost the Market GrowthInfrared And Terahertz Spectroscopy Market Growing Demand to Boost the Market Growth
taiwannews.com.tw - May 2 at 8:53 AM
Global Phytopathological Disease Diagnostics Market Expected to Reach US$ 130.6 Million by 2029Global Phytopathological Disease Diagnostics Market Expected to Reach US$ 130.6 Million by 2029
fmiblog.com - May 2 at 8:53 AM
New dyes and antibody markers for enhanced immunology researchNew dyes and antibody markers for enhanced immunology research
labmate-online.com - May 2 at 8:53 AM
Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare ConferenceBio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - May 1 at 10:14 AM
Bio-Rads Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare ConferenceBio-Rad's Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
businesswire.com - May 1 at 9:00 AM
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
zacks.com - April 30 at 11:06 AM
Bio-Rad Laboratories (BIO) Scheduled to Post Earnings on TuesdayBio-Rad Laboratories (BIO) Scheduled to Post Earnings on Tuesday
marketbeat.com - April 30 at 10:09 AM
In Vitro Diagnostics (IVD) Market: Overview of Industry Leaders and Innovations | CAGR 4.1%In Vitro Diagnostics (IVD) Market: Overview of Industry Leaders and Innovations | CAGR 4.1%
pharmiweb.com - April 30 at 10:08 AM
Anchor Capital Advisors LLC Sells 20,844 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Anchor Capital Advisors LLC Sells 20,844 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)
marketbeat.com - April 29 at 5:26 PM
Bio-Rad Laboratories (NYSE:BIO) Rating Increased to Buy at StockNews.comBio-Rad Laboratories (NYSE:BIO) Rating Increased to Buy at StockNews.com
americanbankingnews.com - April 29 at 5:10 AM
IFM Investors Pty Ltd Makes New Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)IFM Investors Pty Ltd Makes New Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)
marketbeat.com - April 28 at 10:42 PM
Bio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesBio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages
americanbankingnews.com - April 28 at 4:10 AM
Sector Gamma AS Makes New $7.62 Million Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)Sector Gamma AS Makes New $7.62 Million Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)
marketbeat.com - April 27 at 4:38 PM
Bio-Rad Announces Life Science Group Management ChangesBio-Rad Announces Life Science Group Management Changes
businesswire.com - April 26 at 8:30 AM
S&P 500 (SPX) today: Top movers are Bio-Rad Laboratories Inc and Agilent Technologies, Inc.S&P 500 (SPX) today: Top movers are Bio-Rad Laboratories Inc and Agilent Technologies, Inc.
usatoday.com - April 23 at 3:09 PM
Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Bought by Duality Advisers LPBio-Rad Laboratories, Inc. (NYSE:BIO) Shares Bought by Duality Advisers LP
marketbeat.com - April 22 at 11:54 AM
Kornitzer Capital Management Inc. KS Cuts Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)Kornitzer Capital Management Inc. KS Cuts Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)
marketbeat.com - April 20 at 11:18 AM
Commit To Purchase Bio-Rad Laboratories At $185, Earn 1.3% Annualized Using OptionsCommit To Purchase Bio-Rad Laboratories At $185, Earn 1.3% Annualized Using Options
nasdaq.com - April 19 at 11:28 PM
New Strong Sell Stocks for April 19thNew Strong Sell Stocks for April 19th
zacks.com - April 19 at 5:26 AM
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
zacks.com - April 18 at 11:06 AM
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
businesswire.com - April 18 at 9:00 AM
Bio-Rad Laboratories, Inc. (NYSE:BIO) to Post Q1 2025 Earnings of $2.39 Per Share, Zacks Research ForecastsBio-Rad Laboratories, Inc. (NYSE:BIO) to Post Q1 2025 Earnings of $2.39 Per Share, Zacks Research Forecasts
marketbeat.com - April 17 at 5:55 PM
Bio-Rad (BIO) Hurt by Softness in BioPharma and CompetitionBio-Rad (BIO) Hurt by Softness in BioPharma and Competition
zacks.com - April 16 at 12:01 PM
Zacks Research Equities Analysts Reduce Earnings Estimates for Bio-Rad Laboratories, Inc. (NYSE:BIO)Zacks Research Equities Analysts Reduce Earnings Estimates for Bio-Rad Laboratories, Inc. (NYSE:BIO)
marketbeat.com - April 16 at 7:27 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Bio-Rad Laboratories logo

Bio-Rad Laboratories

NYSE:BIO
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.